Randomised three-armed trial investigation of the Copenhagen Achilles tendon Rupture Treatment Algorithm (CARTA) for individualised treatment of acute Achilles tendon rupture Authors: Marianne Toft, Maria Swennergren Hansen, Jannie Dybsoe Vestergaard, Julie Jenlar, Anna Kathrine Pramming, Stefan Møller, Bjørn Slott Korvenius Nedergaard, Morten Tange Kristensen, Louise Lau Simonsen, Bjarke Viberg, Per Hölmich, Kristoffer W Barfod Published: 2026 ABSTRACT AbstractObjectiveTo evaluate whether individualised treatment using the Copenhagen Achilles Rupture Treatment Algorithm (CARTA) is superior to default operative or non-operative strategies.MethodsWe conducted a multicentre, three-arm, randomised controlled trial. Adults with acute Achilles tendon rupture were randomised (1:1:1) to individualised CARTA, non-operative or operative treatment. In the CARTA arm, surgery was indicated if ultrasound showed<25% tendon overlap or ≥7% elongation. The primary outcome was the Heel-Rise Work Test (HRWT) at 12 months. Secondary outcomes included HRWT at 6 months, and at both 6 and 12 months, the Heel-Rise Height, Achilles tendon Total Rupture Score (ATRS), Tegner activity scale, Copenhagen Achilles tendon Length Measure, Achilles Tendon Resting Angle (ATRA) and complication recordings.ResultsBetween May 2018 and June 2023, 970 patients were screened; 300 were randomised (male/female 76%/24%, mean age 41 (SD 1)). At 12 months, data were available for 98 CARTA (64% operated), 100 non-operative and 97 operative patients. There were no significant between-group differences in HRWT at 12 months. However, CARTA significantly reduced rerupture rates by 73% compared with non-operative treatment (3% (95% CI) (1 to 8) vs 11% (6 to 19), p=0.03), improved ATRS by 8 points (1 to 15, p=0.02) and improved ATRA by −2° (−4 to −1), p=0.01). No difference between CARTA and operative treatment was found except 36% less underwent surgery.ConclusionIndividualised CARTA did not improve functional outcomes based on the HRWT at 12 months, but among secondary outcomes, it reduced rerupture rates and improved patient-reported outcomes compared with non-operative treatment and with fewer surgeries than routine operative care.Trial registration numberNCT03525964. WHAT IS ALREADY KNOWN ON THIS TOPIC Acute Achilles tendon rupture treated operatively is known to have a lower rerupture rate than non-operative treatment but with an increase in other adverse events and no influence on functional outcome. Acute Achilles tendon rupture treated operatively is known to have a lower rerupture rate than non-operative treatment but with an increase in other adverse events and no influence on functional outcome. WHAT THIS STUDY ADDS The present study found that a novel ultrasound-based individualised treatment algorithm, the Copenhagen Achilles Rupture Treatment Algorithm (CARTA), led to no difference in functional outcomes based on the Heel-Rise Work Test, but among secondary outcomes CARTA reduced reruptures by 72% and improved Achilles tendon Total Rupture Score compared with non-operative treatment. The present study found that a novel ultrasound-based individualised treatment algorithm, the Copenhagen Achilles Rupture Treatment Algorithm (CARTA), led to no difference in functional outcomes based on the Heel-Rise Work Test, but among secondary outcomes CARTA reduced reruptures by 72% and improved Achilles tendon Total Rupture Score compared with non-operative treatment. CARTA provided a 36% reduction in surgical treatment compared with routine operative management with no difference in outcomes. CARTA provided a 36% reduction in surgical treatment compared with routine operative management with no difference in outcomes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Individualised CARTA was safe for athletes of all levels and offers a resource-efficient strategy for healthcare systems. Further studies and external validation are warranted to confirm our findings. Individualised CARTA was safe for athletes of all levels and offers a resource-efficient strategy for healthcare systems. Further studies and external validation are warranted to confirm our findings. Background Achilles tendon rupture (ATR) is a common, debilitating injury managed operatively or non-operatively.1 2 Non-operative treatment has a higher rerupture rate, while operative treatment increases infection and nerve injury risk, with no clear difference in long-term patient-reported or functional outcomes.35 For athletes, small functional gains may justify surgery, but unnecessary operations and complications should be avoided for safety and cost reasons.6 7 A knowledge gap persists as to whether it is possible to individualise treatment and only select those who truly benefit for surgical treatment. With the present treatment algorithm, we aimed to extract the benefits from both treatment strategies by introducing the rationale of individualised medicine.8 The Copenhagen Achilles tendon Rupture Treatment Algorithm (CARTA) uses ultrasonographic assessment (characterisation of the diastasis by overlap and elongation) to guide treatment, aiming to optimise healing by matching intervention to rupture morphology.2 9 CARTA is based on Amlang’s method for determining tendon end overlap and Copenhagen Achilles tendon Length Measure (CALM) for determining elongation.1012 We investigated whether individualised treatment with CARTA was superior to default operative or non-operative care, hypothesising improved limb symmetry index (LSI) (Heel-Rise Work Test; HRWT) at 12 months. Methods Trial design This prospective, multicentre, randomised clinical trial (ClinicalTrial.gov NCT03525964) included patients from five Danish orthopaedic departments, following CONSORT 2025 guidelines. No protocol changes occurred except extending eligibility from 4 to 7 days postrupture. Protocol is published in trials.13 Patient and public involvement Patients were not involved in the development of the protocol in 2016–2017, where knowledge of beneficial contributions by patient was less evident. Participants Subjects 18 to 65 years of age, who were diagnosed with acute ATR in the emergency department, were immobilised in a low splint in maximal, comfortable plantar flexion of the ankle. Within 7 days, patients were seen in the outpatient clinic and screened for eligibility by interview and examination. Inclusion criteria were: Acute total ATR (palpable gap, no ability to do a single-legged heel lift and Calf-squeeze-test without plantar flexion of the foot). Acute total ATR (palpable gap, no ability to do a single-legged heel lift and Calf-squeeze-test without plantar flexion of the foot). Inclusion appointment in the outpatient’s department within 7 days of injury. Inclusion appointment in the outpatient’s department within 7 days of injury. Initial treatment with low split plaster cast or walker boot with four evenly declining wedges with the ankle in maximally comfortable plantar flexion started within 24 hours of injury. The plantarflexion in boot or cast was checked at time of inclusion, and the patient was excluded and categorised as ‘initial treatment delayed’ if the ankle was not firmly fixed in at least 20° of plantarflexion. Initial treatment with low split plaster cast or walker boot with four evenly declining wedges with the ankle in maximally comfortable plantar flexion started within 24 hours of injury. The plantarflexion in boot or cast was checked at time of inclusion, and the patient was excluded and categorised as ‘initial treatment delayed’ if the ankle was not firmly fixed in at least 20° of plantarflexion. The patient must be expected to be able to attend rehabilitation and follow-ups. The patient must be expected to be able to attend rehabilitation and follow-ups. Patients must be able to speak and understand Danish, and able to give informed consent. Patients must be able to speak and understand Danish, and able to give informed consent. Exclusion criteria were: Rupture of the Achilles tendon within 1,5 cm of the calcaneus or at the musculotendinous junction of the triceps surae muscles. Rupture of the Achilles tendon within 1,5 cm of the calcaneus or at the musculotendinous junction of the triceps surae muscles. Previous rupture of the Achilles tendon in either leg. Previous rupture of the Achilles tendon in either leg. Treated with fluoroquinolones or corticosteroids within the last 6 months or being medically treated for diabetes. Treated with fluoroquinolones or corticosteroids within the last 6 months or being medically treated for diabetes. Other conditions prior to the injury resulting in reduced function of either leg. Other conditions prior to the injury resulting in reduced function of either leg. Contraindication for surgery: severe arthrosclerosis with no palpable pulse in the foot, broken skin in the Achilles region of the injured leg. Contraindication for surgery: severe arthrosclerosis with no palpable pulse in the foot, broken skin in the Achilles region of the injured leg. Inability to lie in the prone position on the operating table. Inability to lie in the prone position on the operating table. Terminal illness or severe medical illness defined as American Society of Anaesthesiologists score ≥3. Terminal illness or severe medical illness defined as American Society of Anaesthesiologists score ≥3. Randomisation and blinding Participants were randomised in blocks of 12 per centre via secure electronic database (Procordo). Outcome assessors were blinded to allocation; patients and surgeons were not. Participants were allocated in parallel fashion 1:1:1 into the three treatment groups: Individualised CARTA treatment. Individualised CARTA treatment. Non-operative treatment. Non-operative treatment. Operative treatment Operative treatment The allocation was performed right after participants’ consent and registration and with two investigators, surgeons and physiotherapists, per centre the allocation was hard to predict. At the follow-up visits after 6 and 12 months, the physiotherapist investigator was blinded for HRWT, maximal heel height and ATRA, by covering the area of the Achilles tendon with a 5 cm wide opaque tape before participants entered the outpatient clinic. The blinding had to be broken, and the tape removed just prior to ultrasonographic CALM, which was the last examination of the evaluation.13 The primary investigator was blinded for treatment allocation during data management and statistical analysis. Intervention—individualised CARTA The intervention group was treated according to the CARTA that determined either operative or non-operative treatment. The ruptured tendon was examined using ultrasonography in a two-step procedure (figure 1). First, the degree of tendon overlap at the rupture site was assessed, following Amlang’s Classification system.10 Second, tendon elongation was evaluated using the CALM method.11 The intervention group was treated according to Copenhagen acute Achilles tendon Rupture Treatment Algorithm (CARTA), where a two-step ultrasonographic examination of tendon overlap and elongation selected participants for either non-operative or operative treatment. Number of participants selected for either treatment is shown for each step of the ultrasonographic examination. CALM, Copenhagen Achilles tendon Length Measure. Tendon overlap: the patient was positioned prone on the examination table, with the knee flexed at 10°–20° and the ankle held in approximately 10° of plantar flexion or matched to the angle of the contralateral ankle. A longitudinal scan was performed to locate the rupture. Once identified, the probe was rotated 90° to obtain a transverse image, and the cross-sectional area of the tendon was assessed. The probe was then moved caudally–cranially to fully evaluate the rupture site. If a transverse view showed less than 25% of tendon fibres within the cross-sectional area of the tendon just proximal to the rupture-site, the rupture was classified as non-overlapping, and patients were treated operatively (figure 1). The intraobserver and interobserver variation for Amlang’s Classification system was unknown. Tendon elongation: this was measured between cranial pole of calcaneus and the most distal muscle fibre of medial gastrocnemius using the CALM method (figure 1).11 Both legs were examined, and the difference in length between sides defined elongation and was expressed as a percentage of the length of the uninjured tendon. Patients with a tendon elongation of up to 7% were treated non-operatively, whereas those with 7% or greater elongation were treated operatively. Treatment For the initial non-operative treatment, the lower leg was immobilised in a circumferential lightweight cast with the ankle in maximally comfortable plantar flexion for 3 weeks followed by a walker boot for 6 weeks.14 The operative treatment was performed under regional anaesthesia within 2 weeks of the injury using a double Kessler suture with size 2 Fiberwire, Arthrex or Orthocord, Johnson and Johnson. Please refer to the protocol paper for a detailed description of the operative technique.13 After the procedure, the lower leg was immobilised in a circumferential lightweight cast for 3 weeks followed by a walker boot for 6 weeks.13 During the 6 weeks in walker boot, plantar flexion was gradually reduced towards neutral position and progressive weightbearing was introduced (figure 2). Thromboprophylaxis of a daily dose of Xarelto 10 mg orally while in circumferential cast was provided as indicated (online supplemental table 1).14 15 Rehabilitation with three daily sets of 10 repetitions of non-resistive ankle dorsi and plantarflexion active range of motion was started when transferred into the boot.16 Week 10–13, participants performed home training exercises followed by 3 months of physiotherapy led standardised rehabilitation programme in the municipality (figure 2 and full description of exercise programme in online supplemental material). Rehabilitation timeline: the timeline of immobilisation, weightbearing and exercises. For the municipal physiotherapist led standardised exercise programme, see online supplemental material for detailed description. Follow-up Follow-up at 6 and 12 months after inclusion started with a 5 min warm up on a stationary bike with minimal load followed by ATRA, the HRWT and lastly the ultrasonographic examination.13 A minimum of two investigators per centre were taught the ultrasonographic technique of CARTA. The length measure CALM proved the harder of the two components to master and was rehearsed until the intra and interobserver variation was reduced to a coefficient of variance of approximately 0.2 (online supplemental table 2).12 17 Throughout the study period, standardisation of the evaluations was maintained by observational visits by the principal investigator at the investigating site. Any adverse events were documented and defined as a complication.13 Outcomes The primary outcome was the HRWT evaluated 12 months after injury. The patient performed heel-lifts until exhaustion, first of the healthy leg and secondary of the injured leg. A transducer was fixed on the heel and connected to the MuscleLab software system (Ergotest Technology, Oslo, Norway) for registration of repetitions and height of the heel lift.13 The result of the HRWT was presented as the relative performance of the injured leg compared with the healthy leg, the LSI, where a minimal important difference of 10%-points is reported.18 The secondary outcomes were evaluated at 6-month and 12-month follow-up: The HRWT was also evaluated as a secondary outcome after 6 months. The Heel-Rise Height (HRH) together with the difference in ATRA between the injured and the healthy leg were investigated as indicative measure for tendon length.19 20 TRA was defined as the angle between the longitudinal axis of the fibula and the longitudinal axis of the fifth metatarsal.20 The ATRS contains 10 questions of 10 grades, from 1 representing completely impairment to 10 of no limitation. A difference down to 7 points was considered a clinically relevant difference.21 The Tegner activity scale consists of 11 defined grades, from 0 representing disability to 10 representing high level activity (professional level football) (online supplemental table 3).22 CALM is an ultrasound-based length measurement. The distance from the calcaneal bone to the most distal muscle fibre of the soleus and medial gastrocnemius muscles was measured.13 Adverse events in the form of thromboembolic event, superficial or deep infection, rerupture, tendon adhesion to skin were continuously registered if they occurred and a systematic screening by questioning was performed at 12-month follow-up. Sample size Sample size was based on detecting a 10-point difference in LSI (SD 20), requiring 84 per group (power 90%, alpha 0.05); 100 per group allowed for dropout.4 23 The trial was not powered specifically to detect any known minimal clinically relevant differences for the secondary outcomes. Statistical methods For the primary outcome, analyses of between-group difference (individualised CARTA treatment vs operative treatment and individualised CARTA treatment vs non-operative treatment) were done using two sample t-test with unequal variance and linear regression analysis in addition. Known risk factors used for adjustment in the linear regressions were sex, age, BMI and ATRS score prior to injury. The model assumption of the linear regression was assessed using residual plots. The primary analysis of the primary outcome was performed following the intention-to-treat principle on imputed data. Missing data were handled by imputation performed by the Multivariate normal imputation model. Secondary analyses were performed as-treated and per-protocol with and without imputations using linear regression for between-group differences. For all continuous secondary outcomes likewise between group differences were using two sample t-test with unequal variance. Binary secondary outcomes were analysed with Fisher’s exact test and proposed logistic regression was optioned out due to risk of introducing error without gaining equivalent reduction in variance based on the randomised design of this investigation.24 Descriptive statistics was presented as mean with SD of the normally distributed data, and as frequencies with percentages for categorical variables. No interim analysis was performed except for the annual review of adverse events. In total, 13 statistical tests were performed with no adjustment for multiple comparisons. Equality, diversity and inclusion statement All genders, ethnicities and socioeconomic backgrounds were eligible. The author group was diverse in gender and career stage. Results Of 970 patients screened for eligibility from June 2018 to June 2023, 101 were allocated to the individualised CARTA treatment, 99 were allocated to operative treatment, and 100 were allocated to non-operative treatment (figure 3). There were 98, 100 and 97 participants available for analysis at 1 year, respectively. In the individualised CARTA group, 65 (64%) participants were selected for operative treatment. There were no differences between groups at baseline (table 1). Flowchart of participants according to eligibility, randomisation, availability for outcome tests at both 6 and 12 months as intention-to-treat. For the exclusion criteria of ‘initial treatment delayed’ includes insufficient plantar flexion of the boot or cast. ATRS, Achilles tendon Total Rupture Score; CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm; HRWT, Heel-Rise Work Test; ITT, intention to treat. Table 1Baseline demographic characteristics, Achilles tendon Total Rupture Score (ATRS) and Tegner Activity Scale score presented as mean (SD), except gender presented as case numbers and proportion of totalIndividualised CARTA, n=101Non-operative, n=100Operative, n=99Male gender77 (76%)78 (78%)73 (74%)Age, years41.3 (0.9)40.1 (1.0)41.6 (1.0)Weight, kg83.8 (1.4)85 (1.2)84 (1.6)Height, cm178.4 (0.9)179.2 (0.9)178 (0.9)ATRS, prerupture96 (1.2)94.2 (1.7)97.9 (0.6)Tegner activity scale, prerupture4.5 (0.2)4.6 (0.2)4.4 (0.2)CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm. Baseline demographic characteristics, Achilles tendon Total Rupture Score (ATRS) and Tegner Activity Scale score presented as mean (SD), except gender presented as case numbers and proportion of total CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm. For the primary outcome, HRWT (LSI) at 12 months, no statistically significant difference was found for individualised CARTA compared with the non-operative (5% (–3 to 12), p=0.20) or with the operative (2% (−5 to 9), p=0.61) (table 2, online supplemental figure 5). Additionally, the 95% CIs for the two control groups of non-operative and operative treatment overlapped (online supplemental table 4). Table 2Outcomes after 6 and 12 monthsIntention-to-treat6 months12 monthsIndividualised CARTANon-operativeOperativeCARTA vs non-operativeCARTA vs operativeIndividualised CARTANon-operativeOperativeCARTA vs non-operativeCARTA vs operativeFunctional outcomesPrimary outcome,n=93n=93n=91n=92n=92n=84HRWT, LSI %49 (30)41 (28)43 (27)8 (−1, 16), p=0.076 (−3, 14), p=0.1769* (25)64* (26)67* (24)5 (−3, 12), p=0.202 (−5,9), p=0.61Length measuresn=89n=90n=91n=91n=91n=88HRH, mm86 (36)80 (35)82 (40)6 (−4, 17), p=0.254 (−8, 15), p=0.52106 (26)103 (27)104 (27)4 (−4, 11), p=0.352 (−6, 10), p=0.61n=96n=94n=91n=92n=94n=89ATRA diff, degrees5 (6)5 (6)5 (6)0 (−2, 2), p=0.810 (−2, 2), p=13 (6)5 (6)4 (8) −2 (−4, −1), p=0.01 −2 (−4, 1), p=0.15n=96n=94n=91n=93n=94n=88CALM gastrocnemius, mm201 (27)200 (23)198 (29)0.4 (−7, 8), p=0.913.1 (−5, 11), p=0.45197 (29)199 (23)198 (26)−2 (−10, 6), p=0.61−0.5 (−9, 8), p=0.91n=43n=48n=39n=46n=54n=45CALM soleus, mm76 (40)71 (27)80 (34)5 (−9, 19), p=0.46−4 (−20, 13), p=0.6478 (40)73 (28)70 (20)6 (−8,19), p=0.808 (−5, 21), p=0.22Patient-reported outcomesn=88n=84n=86n=97n=99n=91ATRS score58 (20)54 (21)53 (22)4 (−2, 10), p=0.175 (−1, 11), p=0.1265 (22)57 (26)61 (−2, 10) 8 (1, 15), p=0.02 4 (−2, 10), p=0.16n=88n=84n=86n=97n=99n=91Tegner activity scale3.7 (1.3)3.5 (1.3)3.4 (1.5)0.2 (−0.2, 0.6), p=0.380.3 (−1, 0.7), p=0.134 (1.6)4 (1.8)3.9 (1.6)0 (−0.5, 0.5), p=10.1 (−0.4, 0.5), p=0.78Presentation of the Intention-To-Treat analysis of means with SD followed by analysis of difference between groups by t-test with 95% CIs. Only the difference in ATRA and ATRS after 12 months between Individualised CARTA and non-operative was statistically significant.*Results of the linear regression analysis for the primary outcome of HRWT, LSI with adjustment for known risk factors is presented in online supplemental table 4 together with the results for as-treated, and per-protocol data both with and without imputation. There was no statistically significant difference between the results of the intention-to-treat analysis and the analysis as-treated and per-protocol.ATRA, Achilles Tendon Resting Angle; ATRS, Achilles Tendon total Rupture Score; CALM, Copenhagen Achilles tendon Length Measure; CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm; HRWT, Heel-Rise Work Test. Outcomes after 6 and 12 months Presentation of the Intention-To-Treat analysis of means with SD followed by analysis of difference between groups by t-test with 95% CIs. Only the difference in ATRA and ATRS after 12 months between Individualised CARTA and non-operative was statistically significant. Results of the linear regression analysis for the primary outcome of HRWT, LSI with adjustment for known risk factors is presented in online supplemental table 4 together with the results for as-treated, and per-protocol data both with and without imputation. There was no statistically significant difference between the results of the intention-to-treat analysis and the analysis as-treated and per-protocol. ATRA, Achilles Tendon Resting Angle; ATRS, Achilles Tendon total Rupture Score; CALM, Copenhagen Achilles tendon Length Measure; CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm; HRWT, Heel-Rise Work Test. For the secondary outcomes, the individualised CARTA group performed statistically significantly better compared with the non-operative group after 12 months with a 73% lower rerupture rate (respectively, 3/101 or 3% (1 to 8) and 11/100 or 11% (6 to 19), p<0.03) (table 3), the ATRS improvement (eight points (1 to 15), p=0.02) and less loss of ATRA (-2.4° (−4.2 to −0.6), p=0.01). High variation for data of the HRWT together with the derived HRH was seen. No statistically significant differences were found between the individualised CARTA treatment and the operative treatment group (table 2). Table 3Reruptures presented as case numbers and means in % with 95% CIs and p value from Fisher’s exact testIndividualised CARTA, N=101Non-operative, N=100Operative, N=97CARTA vs non-operativeCARTA vs operativeMajor adverse eventsRerupture3111%3.0 (0.6 to 8.4)11 (5.6 to 18.8)1.0 (0 to 5.6)p=0.03p=0.62Pulmonary embolism110Deep infection001Total4122Pulmonary embolism and deep infections presented as case numbers.CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm. Reruptures presented as case numbers and means in % with 95% CIs and p value from Fisher’s exact test Pulmonary embolism and deep infections presented as case numbers. CARTA, Copenhagen Achilles tendon Rupture Treatment Algorithm. Three reruptures were seen in the individualised CARTA group, 1 in 65 among the operatively treated, as in the operative group, and 2 in 34 among the non-operatively, which is two reruptures less than expected by random allocation to operative and non-operative treatment. Patients suffering from rerupture were offered operative treatment. One case of pulmonary embolism was diagnosed in both the individualised CARTA, who had received operative treatment, and the non-operative group, and for the operative one case of deep infection of the tendon occurred, which required surgical removal of the full tendon with subsequent loss of ability to do sports and returned only to part-time employment. Major adverse events are presented in table 3, and with all adverse events including deep venous thrombosis presented in online supplemental table 5. No change in statistically significant difference was found for the primary outcome between analysing datasets of intention to treat, as treated, per protocol or with imputation (online supplemental table 4). Discussion The CARTA was designed to provide an individualised ultrasonographic approach to guide treatment decisions in patients with acute ATR. We did not demonstrate a statistically significant advantage in the primary outcome, the HRWT. Secondarily, individualised CARTA treatment showed a reduction in surgical activity of 36% compared with the operative group with no effect on other outcomes but reduced the rerupture rate with 73% compared with the non-operative group and improved patient reported outcomes. Operative treatment had the lowest risk of rerupture, thou not statistically significant, confirming the findings of previous studies and may be of utmost importance for athletes.25 Hence, a selection algorithm selecting more than half of patients for operative treatment was expected to reduce the rate of rerupture when compared with non-operative treatment but still, the relative risk was reduced by 40%. In the operative group, one case of deep infection with subsequent loss of the Achilles tendon was seen, which would most likely put an end to an athlete’s career. To minimise intergroup variation, also the operative group was immobilised for 9 weeks which may contrast with some standard operative protocols of 6 weeks immobilisation. The longer immobilisation could have adversely influenced the functional outcome of the operative group. Still, the potential for confounding is considered minimal. Thus, the non-inferiority study by Westin et al, comparing operative treatment with 6 weeks of immobilisation versus non-operative treatment with 8 weeks of immobilisation of ATRs, found no difference in function at 12 months.5 The individualised CARTA group demonstrated a statistically significant and possibly clinically relevant 8-point improvement in ATRS compared with the non-operative group. A 7-point difference has been found to be the minimally important difference in the Danish translation of the ATRS.21 The finding was surprising considering earlier studies inability to show clinically relevant differences in ATRS between non-operative and operative treatment groups.26 The observed difference may be attributed to the superiority of individualised CARTA over non-operative treatment but could also result from a placebo effect associated with receiving the hypothesised optimal treatment in a non-blinded study design. Adjustment of time to surgery and deep venous thrombosis was not performed for any possible influence on the ATRS.27 28 In the assessment of Achilles tendon length after 6 and 12 months, no significant between-group differences were observed using the direct ultrasound measurement (CALM) or the indicative measure of HRH.29 However, the indicative measure, ATRA, demonstrated reduced elongation in the individualised CARTA group compared with the non-operative group, but the difference was at the level of SE of the mean.30 The discrepancy in results among these length measurement techniques complicates clinical interpretation and questions the relevance of these findings.20 31 Implication of the study The individualised CARTA selection algorithm might be a feasible strategy to reduce surgery and improve patient-reported outcome without increasing the risk of rerupture. Reducing the cost of surgical procedures and major adverse events is of importance to athletes of all levels and to maximise benefit of the scarce resources in the national healthcare systems.7 Strengths and limitations The principal strength of this study was its rigorously controlled randomised design and a sound sample size. However, several limitations should be considered. First, missing data may have introduced bias as data imputation cannot fully substitute for missing values.32 33 Second, the pragmatic rehabilitation protocols implemented in the municipal setting may have contributed to variability in data and/or unknown confounding. Third, for a rigorous design, the same protocol for immobilisation was used but may be less in line with clinical practice of shorter immobilisation with operative treatment. Fourth, the lack of a power calculation for the secondary outcomes limits the interpretability of these findings and makes causal claims impossible. Fifth, the statistically significant improvement in ATRS for the individualised CARTA compared with non-operative treatment may, in part, be attributable to a placebo effect associated with the perception of receiving optimal care. Sixth, the ultrasonographic technique for individualised CARTA was an unfamiliar method for all prior to study start. However, it required minimal training and was rapidly adopted with minimal measurement error across all inclusion sites. Seventh, the use of fixed-block randomisation may have allowed for unblinding of participants at smaller inclusion sites, and finally, the lack of blinding of the US length assessments may have introduced bias. Eighth, the complication rates were based on small case numbers and warrant external validation in future studies. Conclusion Individualised CARTA treatment did not result in better HRWT 12 months after ATR. However, among secondary outcomes, for CARTA, a 73% reduction in rerupture rate and 8-point better ATRS compared with non-operative treatment was observed with 36% fewer surgeries than routine operative care. Protocol Individualised treatment for acute Achilles tendon rupture based on the Copenhagen Achilles Rupture Treatment Algorithm (CARTA): a study protocol for a multicentre randomized controlled trial.13 Approximately halfway through the study period, the time before inclusion interview was extended from 4 to 7 days. Supplementary material